Trans Tech Diagnostics (Q4301091): Difference between revisions
Jump to navigation
Jump to search
(Added qualifier: reason for deprecation (P354): 2016 NUTS 3 statistical territorial entity (Q2576750)) |
(Changed an Item: Deprecated NUTS Before recalculating) |
||
| Property / contained in NUTS: Arrondissement of Hasselt / rank | Property / contained in NUTS: Arrondissement of Hasselt / rank | ||
Deprecated rank | |||
Revision as of 15:23, 27 August 2022
Project Q4301091 in Germany, Belgium, Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Trans Tech Diagnostics |
Project Q4301091 in Germany, Belgium, Netherlands |
Statements
0 references
1,580,000.0 Euro
0 references
3,160,000.0 Euro
0 references
50.0 percent
0 references
1 February 2016
0 references
31 December 2020
0 references
Universiteit Maastricht
0 references
51°8'10.61"N, 4°13'18.23"E
0 references
51°0'2.56"N, 5°28'48.04"E
0 references
51°0'2.84"N, 5°28'47.46"E
0 references
50°46'32.30"N, 6°5'41.17"E
0 references
50°51'9.25"N, 4°43'36.05"E
0 references
50°49'26.44"N, 5°41'45.67"E
0 references
51°12'49.57"N, 5°5'56.72"E
0 references
51°28'27.23"N, 5°26'42.83"E
0 references
50°56'0.92"N, 5°20'32.32"E
0 references
50°50'6.50"N, 5°42'58.46"E
0 references
52°22'37.60"N, 4°53'37.39"E
0 references
51°43'43.54"N, 5°14'51.32"E
0 references
Cardiovascular diseases are the number one killer in the European Union and cost the European community € 196 billion per year. € 106 billion of this budget is spent on health care, including diagnosis and treatment of patients. The rapidly ageing population in the border region creates the expectation that cardiovascular disease will have a strongly increasing negative impact on our society. A large proportion of people with cardiovascular disease shows no serious symptoms during the development of the disease, and is therefore not under treatment. Better and earlier identification of these individuals with an increased health risk is highly desirable. Also, a proper diagnosis for already identified patients is essential to refine the therapy, and to have fewer side effects or complications. ‘TTD’ therefore focuses on the development of a diagnostic kit. This form of personalized health care is seen as the way to more efficient cardiovascular health care, versatile and with fewer additional health damages and costs to the individual and society. These efforts will eventually not only have a positive effect on health care, but also respond to the needs and demands of business and health care providers. (English)
0 references